跳至主要内容
临床试验/JPRN-jRCT2071210085
JPRN-jRCT2071210085已完成1 期

Clinical pharmacology study of K-237 in healthy adult volunteers

Tanigawa Ryohei0 个研究点目标入组 23 人开始时间: 2021年10月26日最近更新:

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
23

研究概览

简要总结

Plasma IVM B1a (unchanged Ivermectin) concentration after K-237 administration can be affected by food. No clinically relevant adverse events or side effects were observed.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 40age old(—)
性别
All

入选标准

  • (1) Subject is a healthy adult volunteer.
  • (2) Subject is between the ages of 20 and 40 years at the time of signing informed consent.
  • (3) Subject has a body mass index of 17.6 to 26.4 kg/m2 at Screening.

排除标准

  • (1) Subject has a supine blood pressure after resting for at least 5 minutes that is lower than 90 mmHg systolic or higher than 140 mmHg systolic, and lower than 40 mmHg diastolic or higher than 90 mmHg diastolic at Screening.
  • (2) Subject has used a drug (including over-the-counter drug) within 14 days before the administration of the study drug or a supplement within 4 weeks before the administration of the study drug, or those who need to use it during the study period.
  • (3) Subject has a current malabsorption, and those who had an operation on the gastrointestinal tract that may affect absorption (excluding appendectomy and treatment for hernia).

研究者

发起方
Tanigawa Ryohei

相似试验